Table 1.
Patient characteristics
| Luminal IDC (n = 1661) | Luminal ILC (n = 104) (n = 104) | ||||
|---|---|---|---|---|---|
| n | % | n | % | P-value | |
| Median follow-up time(months) | 53 | 49.5 | |||
| Age(years) | |||||
| Median | 53 | 53 | |||
| < 50 | 678 | 40 | 44 | 42 | |
| ≧50 | 982 | 59 | 60 | 57 | 0.768 |
| Menopause status | |||||
| Pre | 812 | 48 | 52 | 50 | |
| Post | 844 | 50 | 50 | 48 | 0.703 |
| Histological grade | |||||
| 1 | 486 | 29 | 68 | 65 | |
| 2 | 875 | 52 | 26 | 25 | |
| 3 | 248 | 14 | 2 | 1 | <0.001 |
| Tumor size | |||||
| T1 | 1174 | 70 | 57 | 54 | |
| T2 | 422 | 25 | 40 | 38 | |
| T3 | 63 | 3 | 7 | 6 | 0.002 |
| ER(Allred score) | |||||
| 3 | 19 | 1 | 0 | 0 | |
| 4 | 31 | 2 | 0 | 0 | |
| 5 | 30 | 2 | 1 | 1 | |
| 6 | 62 | 4 | 5 | 5 | |
| 7 | 246 | 15 | 15 | 14 | |
| 8 | 1273 | 76 | 83 | 80 | 0.575 |
| HER2 status | |||||
| 0 | 439 | 26 | 25 | 24 | |
| 1 | 995 | 60 | 67 | 64 | |
| 2(FISH-) | 227 | 14 | 12 | 12 | 0.682 |
| Lymph node status | |||||
| Positive | 489 | 29 | 34 | 32 | |
| Negative | 1021 | 61 | 61 | 58 | 0.492 |
| Initial surgical treatment | |||||
| BCS | 779 | 47 | 41 | 39 | |
| Mastectomy | 882 | 53 | 63 | 61 | 0.007 |
| Positive margins | 38 | 2.2 | 7 | 6.7 | 0.016 |
| Endocrine therapy | |||||
| Yes | 1424 | 85 | 99 | 95 | |
| No | 231 | 13 | 5 | 4 | 0.008 |
| Chemotherapy | |||||
| Yes | 672 | 40 | 44 | 42 | |
| No | 982 | 59 | 60 | 57 | 0.735 |
IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, FISH fluorescent in situ hybridization, BCS breast conserving surgery